Historically, it has been difficult to protect babies and young children from RSV, but in 2023, the Centers for Disease Control and Prevention (CDC) recommended the use of a monoclonal antibody preparation, called nirsevimab (Beyfortus™), to protect the most susceptible infants against RSV. In this video, Dr. Paul Offit, Director of the Vaccine Education Center, discusses this new product as well as its effectiveness in clinical trials, who should receive it and when.
To learn more about vaccines, please visit [ Ссылка ].
Preventing RSV in Babies: A Scientific Milestone
Теги
What is RSV?RSV SymptomsProtecting babies from RSVRSV monoclonal antibodyNirsevimab for babiesBeyfortus for babiesNirsevimab and RSV in babiesBeyfortus and RSV in babiesPreventing RSV in childrenPreventing respiratory syncytial virus in childrenRSV in pediatric patientsWho should get Nirsevimab?Who should get Beyfortus?How effective is Nirsevimab?How effective is Beyfortus?Vaccine Education CenterChildren's Hospital of PhiladelphiaDr. Offit
